PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-3.02
Negative P/E while CRVO shows 1.78. Joel Greenblatt would examine path to profitability versus competitor.
No Data
No Data available this quarter, please select a different quarter.
3.68
P/B above 1.5x CRVO's 1.60. Michael Burry would check for potential asset overvaluation.
-14.36
Negative FCF while CRVO shows P/FCF of 5.66. Joel Greenblatt would examine cash flow improvement potential.
-14.40
Negative operating cash flow while CRVO shows P/OCF of 5.66. Joel Greenblatt would examine operational improvement potential.
3.68
Fair value ratio above 1.5x CRVO's 1.60. Michael Burry would check for mean reversion risks.
-8.29%
Negative earnings while CRVO shows yield of 14.07%. Joel Greenblatt would examine path to profitability.
-6.96%
Negative FCF while CRVO shows yield of 17.68%. Joel Greenblatt would examine cash flow improvement potential.